Design, Synthesis and Pharmacological Evaluation Of

Total Page:16

File Type:pdf, Size:1020Kb

Design, Synthesis and Pharmacological Evaluation Of ogy iol : Op r B e a n l A u c c c e l e Ajeet et al., Mol Biol 2018, 7:2 o s s M Molecular Biology: Open Access DOI: 10.4172/2168-9547.1000206 ISSN: 2168-9547 Research Article Open Access Design, Synthesis and Pharmacological Evaluation of Sulfonamide Derivatives Screened Against Maximal Electroshock Seizure Test Ajeet1*, Kumar A2 and Mishra AK1 1Drug Design Laboratory, School of Pharmaceutical Sciences, IFTM University, Moradabad, India 2Department of Pharmaceutical Chemistry, S. D. College of Pharmacy and Vocational Studies,Muzaffarnagar , India Abstract A series of substituted 4-amino-benzene sulfonamides were designed, keeping in view the structural requirement of pharmacophore. Lipinski rule of five has also been calculated; failure to Lipinski rule was not observed. The synthesized compounds were evaluated for anticonvulsant. Docking was performed through AutoDock Vina. Molecules have been screened out through docking. Compounds were synthesized and characterized through IR, 1HNMR, 13C NMR, Mass and elemental analysis. The anticonvulsant activity of the synthesized compounds was assessed using the MES model. In-silico biological activity spectrum, toxicological studies, predicted oral rat LD50 and possible mechanism of action were investigated. The compound, 4-[2-(4-Acetyl-phenylamino)-ethyl]-benzenesulfonamide (K23) is found most active among the synthesized compounds. Keywords: Anticonvulsant; Sulfonamide; Docking; In-silico studies; activity-relationship (SAR) models; (iv) Ligand-protein docking studies Synthetic compounds of designed compounds; (v) Toxicity estimation of designed compound and (vi) Evaluation of possible pharmacological properties designed Introduction compounds. The newly designed compounds, which follow the criteria considered in multiple computational studies, are preceded for Epilepsy is one of the serious disorders with no age, sex or racial synthesis, structural elucidation and further experimental evaluation of boundaries. Epilepsy imposes a large economic burden on health care activities. systems of countries. There is also a hidden burden associated with stigma and discrimination against the patient and even their family In this paper, we have designed and synthesized compounds in the community, workplace, and home. In general, the patients with as carbonic anhydrase inhibitors, keeping in view the structural epilepsy suffer severe emotional distress, behavioral disorders and requirement of pharmacophore. All the designed compounds were extreme social isolation [1]. initially gone through in-silico screening like Lipinski rule, QSAR modeling & screening and docking studies. The screened compounds Epilepsy is usually associated with recurrent seizures. This implies were then synthesized and gone through analytical studies like IR, NMR that epilepsy is an ancient disorder; indeed, in all civilizations it can be and Mass spectroscopy. After that all the synthesized compounds were traced as far back as medical records exist. In fact, epilepsy is a disorder treated for pharmacological screening. An In-silico biological activity that can occur in all mammalian species, probably more frequently spectrum, toxicological studies, predicted oral rat LD50, possible as brains have become more complex. Epilepsy is also remarkably mechanism of action and SAR studies were also investigated. uniformly distributed around the world [2]. Steps followed for completing the current research work is shown Among the reported potential agents to treat the epilepsy, in following illustration Figure 1. sulphonamides are important and their significance cannot be ignored. Sulphonamides are of high attention for various pharmacological Materials and Methods importance, as it is reported for chiefly anticonvulsant [3,4], antitubercular [5,6] and antimicrobial activities [7,8]. For all these Designing of molecules activities, the suphonamide derivatives are reported with multiple Identification of pharmacophoric groups was done from the scaffolds such as Sulfonamides incorporating Valproyl derivatives, structures of well-known anticonvulsants. The structures of well-known Sulfamates, Sulfamides, Thiazolidin derivatives, Aminobenzamides, anticonvulsants and identified pharmacophore are presented in Table 1 Beta-Ketosulfonamide etc [3-8]. [9,10]. The essential structural features which could be responsible for an interaction with the active site were a hydrophobic (HP) unit, an electron Being inspired from the previous developments, there is always donor (D) group, and a hydrogen donor/acceptor (HD/HA) unit. an enthusiasm to design of novel sulphonamide with many scaffolds and to evaluate their possible pharmacological properties as well as mechanism of action. These novel designs will support for future drug developments for multiple diseases in human health care. There is *Corresponding author: Ajeet, Drug Design Laboratory, School of Pharmaceutical always a chance to get a potential compound on hit and trial basis for Sciences, IFTM University, Moradabad, Uttar Pradesh, India, Tel: +91-9236817425; design and synthesis of novel compounds. Beyond this, at present multi- E-mail: [email protected] disciplinary protocols are being suggested to screen the designed-only Received February 06, 2018; Accepted February 21, 2018; Published February compounds through computational methods to get the possibility of 28, 2018 pharmacological importance of compounds prior to their synthesis and Citation: Ajeet, Kumar A, Mishra AK (2018) Design, Synthesis and Pharmacological in-vitro experiments. Sequential computational procedures include: (i) Evaluation of Sulfonamide Derivatives Screened Against Maximal Electroshock Collection of information about scaffolds, linkers and side-groups for Seizure Test. Mol Biol 7: 206. doi: 10.4172/2168-9547.1000206 possible novel compound; (ii) Structural designing of location specific Copyright: © 2018 Ajeet, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted derivative combinations with one or more scaffold; (iii) Virtual- use, distribution, and reproduction in any medium, provided the original author and screening of activity of designed compounds through structure- source are credited. Mol Biol, an open access journal Volume 7 • Issue 2 • 1000206 ISSN: 2168-9547 Citation: Ajeet, Kumar A, Mishra AK (2018) Design, Synthesis and Pharmacological Evaluation of Sulfonamide Derivatives Screened Against Maximal Electroshock Seizure Test. Mol Biol 7: 206. doi: 10.4172/2168-9547.1000206 Page 2 of 10 D HA HP O N N HP S D N O H D NH2 HD Albutoin Carbamazepine HD H H OH HD D N N N H H O D HA H N N N Figure 1: Complete steps followed during research work. HA HP H Cl O HA Gabapentin Cl HA Lamotrigine O N NH HD HA H N 2 S O O O HA HD HA O O D Ethosuximide N NH Zonisamide HD O O Methylphenobarbital N OH HA O HD D H N H S HA F N HD H HP HN O D Cl Cl Progabide Ralitoline D D Basic identified pharmacophore H O N H Table 1: Pharmacophoric pattern of well-known anticonvulsants. N HN HD NH O H HA Docking studies HA HD O Docking tool: Docking was performed with AutoDock Vina HP (PyRx-Python Prescription 0.8) docking software [11]. It is virtual HP screening software for computational drug discovery that can be used to screen libraries of compounds against potential drug targets. It Phenytoin Remacemide enables medicinal chemists to run virtual screening form any platform and helps users in every steps of this process from data preparation to job submission and analysis of the results [12]. Receptor: Lyase (Oxo-acid)-Human Carbonic Anhydrase-I. Mol Biol, an open access journal Volume 7 • Issue 2 • 1000206 ISSN: 2168-9547 Citation: Ajeet, Kumar A, Mishra AK (2018) Design, Synthesis and Pharmacological Evaluation of Sulfonamide Derivatives Screened Against Maximal Electroshock Seizure Test. Mol Biol 7: 206. doi: 10.4172/2168-9547.1000206 Page 3 of 10 Experimental: All the chemicals and solvents, purchased from Merck (India), Spectrochem (India), Sigma-Aldrich (India), Hi-Media H (India) and S.D. Fine (India) were used without further purification. N C SO NH Thin layer chromatographic (TLC) analysis of compounds was Cn n 2 2 performed on silica gel G coated glass plates. The adsorbent silica gel Cl H G was coated to a thickness of about 0.3 mm on previously cleaned TLC plates of 20x5 cm2 using conventional spreader. The plates were placed in hot air oven at 105°C for 30 min. The solutions of compounds R were applied as a spot on the activated plate about 2 cm above from the lower edge. The mobile phases were selected according to the polarity of compounds. H R N Cn Melting points were determined by using open capillary melting HCl gas Cn point apparatus and are reported uncorrected. The 1H-NMR spectra were recorded on Avance-III, Bruker, 400 MHz High Resolution NMR spectrometer and C13-NMR were recorded with Avance-III, Bruker, 100 MHz. Signals were described as singlet (s), doublet (d), triplet (t) SO2NH2 and multiplet (m). FT-IR spectra (KBr) were recorded on a Perkin- Common reaction mechanism of schemes employed. Elmer Spectrometer BX-II spectrophotometer. The mass spectra were Figure 3: recorded on a Waters Micro-Mass ZQ 2000 mass spectrometer. Synthetic scheme in 50 ml. of dry acetone. After addition, the reaction mixture was stirred for about 12 hour at room temperature and then the solvent was Shown in following illustration Figure 2. evaporated under reduced pressure. The residue was dissolved in 100 Mechanism of
Recommended publications
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan
    US008357723B2 (12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan. 22, 2013 (54) PRODRUGS CONTAINING NOVEL "Nitric Oxide Donors and Cardiovascular Agents Modulating the BO-CLEAVABLE LINKERS Bioactivity of Nitric Oxide: An Overview” by Louis J. Ignarro, et al., Circulation Research, vol. 90, No. 1, pp. 21-22 (Jan. 11, 002). (75) Inventor: Apparao Satyam, Mumbai (IN) “Bis3-(4-substituted phenyl)prop-2-enedisulfides as a new class of (73) Assignee: Piramal Enterprises Limited and antihyperlipidemic compounds' by Meenakshi Sharma, et al., Apparao Satyam, Mumbai (IN) Bioorganic and Medicinal Chemistry Leters, vol. 14, No. 21, pp. (*) Notice: Subject to any disclaimer, the term of this 5347-5350 (Nov. 1, 2004). patent is extended or adjusted under 35 Abstract Only "Spectrophotometric determination of binary mix U.S.C. 154(b) by 0 days. tures of pseudoephedrine with some histamine H1-receptor antago nists using derivative radio spectrum method' by H. Mahgouh, et al., (21) Appl. No.: 12/977,929 J. Pham Biomed Anal, vol. 31, No. 4, pp. 801-809 Mar. 26, 2003. (22) Filed: Dec. 23, 2010 Peter D. Senter et al., Development of Drug-Release Strategy Based (65) Prior Publication Data on the Reductive Fragmentation pf Benzyl Carbamate Disulfides. Journal of Organic Chemistry, 1990, 55, 2975-2978. Published by US 2011 FO269709 A1 Nov. 3, 2011 American Chemical Society (USA). Related U.S. Application Data Vivekananda M. Virudhula et al., Reductively Activated Disulfide Prodrugs of Paclitaxel. Biorganic & Medicinal Chemistry Letters, (62) Division of application No. 1 1/213,396, filed on Aug.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials
    ILAE 110th anniversary review paper* Epileptic Disord 2019; 21 (4): 319-29 Antiepileptic drugs: evolution of our knowledge and changes in drug trials Emilio Perucca Past President of the International League Against Epilepsy Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia and IRCCS Mondino Foundation, Pavia, Italy Received April 30, 2019; Accepted June 01, 2019 ABSTRACT – Clinical trials provide the evidence needed for rational use of medicines. The evolution of drug trials follows largely the evolution of regulatory requirements. This article summarizes methodological changes in antiepileptic drug trials and associated advances in knowledge starting from 1938, the year phenytoin was introduced and also the year when evi- dence of safety was made a requirement for the marketing of medicines in the United States. The first period (1938-1969) saw the introduction of over 20 new drugs for epilepsy, many of which did not withstand the test of time. Only few well controlled trials were completed in that period and trial designs were generally suboptimal due to methodological constraints. The intermediate period (1970-1988) did not see the introduction of any major new medication, but important therapeutic advances took place due to improved understanding of the properties of available drugs. The value of therapeutic drug monitoring and monotherapy were recognized dur- ing the intermediate period, which also saw major improvements in trial methodology. The last period (1989-2019) was dominated by the introduc- tion of second-generation drugs, and further evolution in the design of monotherapy and adjunctive-therapy trials. The expansion of the pharma- cological armamentarium has improved opportunities for tailoring drug treatment to the characteristics of the individual.
    [Show full text]
  • P=.004), Comparable. Median Post-LT VPA-ALF Contraindicated for Acute
    and 76% were due to neurocysticercosis. (Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology April 12, 2011;76:1338-1343). (Response and reprints: Dr Sheffali Gulati, Department of Pediatrics, AIIMS, Ansari Nagar, New Delhi, 110 029, India. E-mail: [email protected] COMMENT. Gingival hyperplasia associated with phenytoin treatment of epilepsy is reported in as few as 3% of cases (Lennox WG, 1940) to as many as 78% (Gardner AF et al, 1962). It occurs more frequently in children than in adults. Numerous mechanisms have been proposed but few of proven significance. Other hydantoin anticonvulsants (mephenytoin, ethotoin, and albutoin) cause little or no gingival hyperplasia. The above investigators have discovered an important and correctable factor in the mechanism in their clinic population. The authors allude to a lack of dental hygiene in a high proportion of patients, a known contributing factor associated with tissue inflammation and irritation. Hyperplasia does not occur in edentulous adults. Phenytoin has an affinity for gingival tissue, and its effect on collagen and keratin in connective tissue has been used in the promotion of healing of wounds and leg ulcers (Shafer WG et al, 1958; Houck JC et al, 1972). In addition to man, only the ferret is susceptible to phenytoin gum hyperplasia, an interesting companion in science. Mechanisms largely disproven include a deficiency of ascorbic acid, adrenocortical dysfunction, and allergy (Gardner, 1962). Hyperglycemia induced by phenytoin, an effect discovered in our neurology research laboratories at Children's Memorial Hospital (Belton NR et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Issue #81-92, 1976
    ISSN 0090-1350 LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedical Communications Network No 81 January 197 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page Journal Citation Data Bases 2 On-line Technical Notes 2 Proposed Conversion from TSO to TCAM Message Handler As NLM's Teleprocessing Interface 5 Hedges , 9 Responsible Use of On-line Data Bases 11 An Experiment in On-Site Training, Madison, Wisconsin — December 15-19, 1975 12 Tumor Key Errata 14 MEDLINE Trainees at the University of Wisconsin, December 15, 1975 14 New Serials Announcement - December 1975 15 MEDLINE Trainees at NLM, January 12, 1976 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedlcal Communications Network JOURNAL CITATION DATA BASES EDITOR Grace H. McCarn Head, MEDLARS Management Section MEDLINE and SDILINS were updated with National Library of Medicine February 1976 citations at NLM and SUNY on 8600 Rockville Pike January 12. The sizes, Index Medicus date Bethesda, Maryland 20014 ranges, and entry date ranges are given (301) 496-6193 TWX: 710-824-9616 below: ASSISTANT EDITOR P.E. Pothier MEDLINE (Jan 74 - Feb 76) - 486,93? (Entry Dates: 731130 to 760102) TECHNICAL NOTES EDITOR Leonard J. Bahlman SDILINE (Feb 76) - 21,138 (Entry Dates: 751210 to 761012) The LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN is issued monthly by the Office of the Associate Director for Library Operations. ON-LINE TECHNICAL NOTES PLEASE QUERY THE NLM/ON-LINE NEWS FILES DAILY FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, in the margin beside each Technical Note., users will be referred to the section/page of the NLM On-Line Services Reference Manual which is considered most relevant to the item being discussed (e.g.., Manual II-9) .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Is Based Partly on a Stored Dictionary and Partly on the Identification of Text
    DOCUMENT RESUME ED 022 504 LI 000 909 By- Artandi, Susan; Baxenda!e, Stanley PROJECT MEDICO; MODEL EXPERIMENT IN DRUG INDEXING BY COMPUTER. FIRSTPROGRESS REPORT. Rutgers, The State Univ., New Brunswick, N.J. Graduate School of Library Service. Spons Agency-Public Health Service (DHEW), Washington, D.C. National Libraryof Medicine. Report No-PHS-LM-94 Pub Date Jan 68 Note- 1 1 1p. EDRS Price MF-$0.50 HC-1,452 Descriptors-*AUTOMATION, COMPUTER PROGRAMS, COMPUTERS, *COMPUTER STORAGE DEVICES, DICTIONARIES, *INDUING,*INFORMATIONRETRIEVAL,*INFORMATION STORAGE, INPUT OUTPUT, OPERATIONS RESEARCH, SEARCH STRATEGIES Identifiers- MEDIrCO, *Model Experiment in Drug Indexing by Computer This report describes Phase 1 of a research project with theover-all objective of exploring the applicability of automatic methods in theindexing of drug information appearing in English natural language text.Two major phases of the research have been completed:(1)development oftheautomaticindexing method andits implementation on the test documents and (2) creation of a machinesearchable file for the storage of the index records generated through automaticincicxing. Indexing is based partly on a stored dictionaryand partly on the identification of text characteristics which can be used to signal to the computerthe presence of information to be indexed. The characteristics of the machine file wereestablished with the desired search capabilities in mind. The file stores documentreferences with their associated index terms. In addition to assigning index terms todocuments the computer program also automatically assignsweights to the index terms to indicate their relative importance in the document 'description. The next two majorphases of the work will involve the design and implementation of the search programand the evaluation of the automatic indexing method.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,199,151 B2 Shashoua Et Al
    US007 1991.51B2 (12) United States Patent (10) Patent No.: US 7,199,151 B2 Shashoua et al. (45) Date of Patent: *Apr. 3, 2007 (54) DHA-PHARMACEUTICAL AGENT 4,692,441 A 9, 1987 Alexander et al. CONUGATES OF TAXANES 4,704,393 A 11/1987 Wakabayashi et al. 4,729,989 A 3, 1988 Alexander (75) Inventors: Victor E. Shashoua, Brookline, MA 4,788,063 A 11/1988 Fisher et al. (US); Charles E. Swindell, Merion, PA is: A RE s al (US); Nigel L. Webb, Bryn Mawr, PA 4s68161. A 9, 1989 Roberts (US); Matthews O. Bradley, 4.902,505 A 2/1990 Pardridge et al. Laytonsville, MD (US) 4,933,324. A 6/1990 Shashoua 4,939,174 A 7, 1990 Shashoua (73) Assignee: Luitpold Pharmaceuticals, Inc., 4,943,579 A 7, 1990 Vishnuvajala et al. Shirley, NY (US) 4,968,672 A 1 1/1990 Jacobson et al. 5,059,699 A 10/1991 Kingston et al. (*) Notice: Subject to any disclaimer, the term of this 5,068,224. A 11/1991 Fryklund et al. patent is extended or adjusted under 35 5, 112,596 A 5/1992 Malfroy-Camine U.S.C. 154(b) by 81 days. 5, 112,863 A 5/1992 Hashimoto et al. 5,116,624 A 5/1992 Horrobin et al. This patent is Subject to a terminal dis- 5, 120,760 A 6/1992 Horrobin claimer. 5,141,958 A 8, 1992 Crozier-Willi et al. 5,169,762 A 12/1992 Grey et al. (21) Appl. No.: 10/618,884 5,169,764 A 12/1992 Shooter et al.
    [Show full text]